Pharmacological Treatment of Children and Adolescents Diagnosed with
Attention-deficit/hyperactivity Disorder at Mental Health Services in Qatar: A
Retrospective Study

Oraib      Abdallah; Nour      Isleem; Rania      Abu-Kuhail; Sali      El Hoseny; Yassin      Eltorki; Noriya      Al Khuzaei

doi:10.2174/04666221229092808

Abstract

Background: Attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children. The consequences of ADHD could seriously impact the patient’s life, and thus parental training, behavioral therapies, and pharmacological interventions are the main therapeutic options applied. This study was conducted to explore the trends of prescribing pharmacological medications used in ADHD and identify the reasons for discontinuation of such medications.

Methodology: A retrospective chart review for patients diagnosed with ADHD at Child and Adolescent Mental Health Services (CAMHS) in Qatar from January 2019 to December 2019 was carried out. Patients less than 18 years old, diagnosed with ADHD as per the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and were on pharmacological treatment for ADHD were suitable to be included. Patients who were not on anti-ADHD medications were excluded from the study.

Results: Ninety-two patients were eligible to be included in the study. Autism Spectrum Disorder (ASD) was found to be the most coexisting condition in addition to ADHD in 16.3%. Methylphenidate was the most prescribed medication (68.5%), followed by atomoxetine (30.4%). None of the participants were found on modafinil, guanfacine, bupropion, or benzodiazepines, and none exceeded the maximum licensed dose of either methylphenidate or atomoxetine. Half (50%) of the sample on atomoxetine discontinued treatment compared to 14.2% in the methylphenidate group.

Conclusion: The clinical practice of prescribing pharmacological options for ADHD was thoroughly in alignment with international guidelines. The effects of long-term use of these psychotropics in this particular group of patients on their neurobiological, behavioral, and physical health should be studied further.

[1]
Beau-Lejdstrom R, Douglas I, Evans SJ, Smeeth L. Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open  2016; 6(6): e010508.
 [http://dx.doi.org/10.1136/bmjopen-2015-010508]

[2]
Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry  2015; 56(3): 345-65.
 [http://dx.doi.org/10.1111/jcpp.12381] [PMID: 25649325]

[3]
Bener A, Qahtani RA, Abdelaal I. The prevalence of ADHD among primary school children in an Arabian society. J Atten Disord  2006; 10(1): 77-82.
 [http://dx.doi.org/10.1177/1087054705284500] [PMID: 16840595]

[4]
Bradshaw LG, Kamal M. Prevalence of ADHD in Qatari school-age children. J Atten Disord  2017; 21(5): 442-9.
 [http://dx.doi.org/10.1177/1087054713517545] [PMID: 24412969]

[5]
Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am  2000; 9(3): 711-26.
 [http://dx.doi.org/10.1016/S1056-4993(18)30114-7] [PMID: 10944664]

[6]
Thapar A, Cooper M, Jefferies R, Stergiakouli E. What causes attention deficit hyperactivity disorder? Arch Dis Child  2012; 97(3): 260-5.
 [http://dx.doi.org/10.1136/archdischild-2011-300482] [PMID: 21903599]

[7]
National Instiutue for health and care excellence. Attention deficit hyperactivity disorder: diagnosis and management [NICE Guideline No. NG87]. 2019.https://www.nice.org.uk/guidance/ng87/resources

[8]
Grimmsmann T, Himmel W. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. Eur J Clin Pharmacol  2021; 77(1): 107-15.
 [http://dx.doi.org/10.1007/s00228-020-02948-3] [PMID: 32803292]

[9]
Antshel KM, Zhang-James Y, Faraone SV. The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother  2013; 13(10): 1117-28.
 [http://dx.doi.org/10.1586/14737175.2013.840417] [PMID: 24117274]

[10]
Giacobini M, Medin E, Ahnemark E, Russo LJ, Carlqvist P. Prevalence, patient characteristics, and pharmacological treatment of children, adolescents, and adults diagnosed with ADHD in Sweden. J Atten Disord  2018; 22(1): 3-13.
 [http://dx.doi.org/10.1177/1087054714554617] [PMID: 25376193]

[11]
Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol  2013; 23(6): 534-41.
 [http://dx.doi.org/10.1016/j.euroneuro.2012.06.011] [PMID: 22796229]

[12]
Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Aust N Z J Psychiatry  2007; 41(3): 222-30.
 [http://dx.doi.org/10.1080/00048670601057767] [PMID: 17464703]

[13]
Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - A systematic literature review. Neuropsychiatr Dis Treat  2014; 10: 1543-69.
 [http://dx.doi.org/10.2147/NDT.S65721] [PMID: 25187718]

[14]
Brown JT, Bishop JR, Sangkuhl K, et al. Clinical pharmacogenetics implementation consortium guideline for CYTOCHROME P450 ( CYP )2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther  2019; 106(1): 94-102.
 [http://dx.doi.org/10.1002/cpt.1409] [PMID: 30801677]